Modulation of Gut Microbiota by Rifaximin in PD Patients
NCT03958708
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Parkinson Disease
Inflammation
Interventions
DRUG:
Rifaximin 550 MG
Sponsor
Taipei Medical University Shuang Ho Hospital